Patents by Inventor Stéphane OUDARD

Stéphane OUDARD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR IDENTIFYING WHETHER A SUBJECT SUFFERING FROM A CANCER WILL ACHIEVE A RESPONSE WITH AN IMMUNE-CHECKPOINT INHIBITOR
    Publication number: 20220107323
    Abstract: The present invention relates to use of soluble CD27 as a biomarker to predict the response to an immune checkpoint inhibitor treatment. Inventors have worked with two cohorts of patients and have identified a soluble marker, CD27, present in the plasma of patients with renal cell cancer whose pre-treatment concentrations predict the response to anti-PD-1/PD-L1. This marker appears more as a predictive marker of response to anti-PD1/PD-L1 treatment, than as a prognostic marker. Indeed, it is not associated with better survival in patients with metastatic renal cell cancer treated with an antiangiogenic agent. This marker is not correlated with conventional clinical markers of severity that classify patients with metastatic renal cancer.
    Type: Application
    Filed: January 29, 2020
    Publication date: April 7, 2022
    Inventors: Eric TARTOUR, Nadine BEN HAMOUDA, Stéphane OUDARD, Nicolas EPAILLARD